stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Return on assets
CG Oncology, Inc.'s return on assets over the twelve months to 30 September 2026 was −26.7%, down 5.9 percentage points from fiscal 2025 (−20.8%). That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −20.8% | (2.37) |
| FY2024 | −18.5% | 20.62 |
| FY2023 | −39.1% | (39.07) |
| FY2022 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| MANE Veradermics Incorporated compare | −20.9% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| SRRK Scholar Rock Holding Corporation compare | −94.6% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement